Smart radiation seeks and destroys resistant prostate cancer

NCT ID NCT07259213

Recruiting now Disease control Sponsor: Radiopharm Theranostics, Ltd Source: ClinicalTrials.gov ↗

First seen Dec 15, 2025 · Last updated May 04, 2026 · Updated 23 times

Summary

This study tests a new radioactive drug (161Tb-RAD402) designed to find and attack prostate cancer cells that no longer respond to standard hormone therapy. About 73 men with castration-resistant prostate cancer will receive the drug to see if it is safe and can shrink tumors or lower PSA levels. The goal is to deliver targeted radiation directly to cancer cells while limiting harm to healthy tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Icon Cancer Centre Hollywood
RECRUITING

Nedlands, Western Australia, 6009, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia

Conditions

Explore the condition pages connected to this study.

CASTRATION-RESISTANT PROSTATE CANCER